

Van-Hai Hoang

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/1179117/publications.pdf>

Version: 2024-02-01

17
papers

277
citations

840728

11
h-index

888047

17
g-index

17
all docs

17
docs citations

17
times ranked

277
citing authors

#	ARTICLE	IF	CITATIONS
1	C-terminal HSP90 inhibitor L80 elicits anti-metastatic effects in triple-negative breast cancer via STAT3 inhibition. <i>Cancer Letters</i> , 2019, 447, 141-153.	7.2	34
2	Structure-activity relationship of human glutaminyl cyclase inhibitors having an N-(5-methyl-1H-imidazol-1-yl)propyl thiourea template. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 3821-3830.	3.0	33
3	Discovery of Potent Human Glutaminyl Cyclase Inhibitors as Anti-Alzheimer's Agents Based on Rational Design. <i>Journal of Medicinal Chemistry</i> , 2017, 60, 2573-2590.	6.4	33
4	TRPV1 antagonist with high analgesic efficacy: 2-Thio pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylamino-phenyl)propanamides. <i>Bioorganic and Medicinal Chemistry</i> , 2013, 21, 6657-6664.	3.0	20
5	Potent human glutaminyl cyclase inhibitors as potential anti-Alzheimer's agents: Structure-activity relationship study of Arg-mimetic region. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 1035-1049.	3.0	19
6	2-Aryl substituted pyridine C-region analogues of 2-(3-fluoro-4-methylsulfonylamino-phenyl)propanamides as highly potent TRPV1 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 4044-4047.	2.2	16
7	Structure-activity relationship investigation of Phe-Arg mimetic region of human glutaminyl cyclase inhibitors. <i>Bioorganic and Medicinal Chemistry</i> , 2018, 26, 3133-3144.	3.0	16
8	Discovery of Conformationally Restricted Human Glutaminyl Cyclase Inhibitors as Potent Anti-Alzheimer's Agents by Structure-Based Design. <i>Journal of Medicinal Chemistry</i> , 2019, 62, 8011-8027.	6.4	16
9	Investigation of B,C-ring truncated deguelin derivatives as heat shock protein 90 (HSP90) inhibitors for use as anti-breast cancer agents. <i>Bioorganic and Medicinal Chemistry</i> , 2019, 27, 1370-1381.	3.0	16
10	In vitro and in silico determination of glutaminyl cyclase inhibitors. <i>RSC Advances</i> , 2019, 9, 29619-29627.	3.6	14
11	Inhibition of Glutaminyl Cyclase Ameliorates Amyloid Pathology in an Animal Model of Alzheimer's Disease via the Modulation of β -Secretase Activity. <i>Journal of Alzheimer's Disease</i> , 2014, 43, 797-807.	2.6	12
12	β -Substituted 2-(3-fluoro-4-methylsulfonylamino-phenyl)acetamides as potent TRPV1 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2015, 25, 2326-2330.	2.2	11
13	A novel HSP90 inhibitor SL-145 suppresses metastatic triple-negative breast cancer without triggering the heat shock response. <i>Oncogene</i> , 2022, 41, 3289-3297.	5.9	11
14	Identifying Possible AChE Inhibitors from Drug-like Molecules via Machine Learning and Experimental Studies. <i>ACS Omega</i> , 2022, 7, 20673-20682.	3.5	11
15	Discovery of highly potent human glutaminyl cyclase (QC) inhibitors as anti-Alzheimer's agents by the combination of pharmacophore-based and structure-based design. <i>European Journal of Medicinal Chemistry</i> , 2021, 226, 113819.	5.5	7
16	β -Methylated simplified resiniferatoxin (sRTX) thiourea analogues as potent and stereospecific TRPV1 antagonists. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2014, 24, 2685-2688.	2.2	5
17	Design, synthesis and bioevaluation of novel 6-substituted aminoindazole derivatives as anticancer agents. <i>RSC Advances</i> , 2020, 10, 45199-45206.	3.6	3